A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Conditions: Solid Tumors; Advanced Triple Negative Breast Cancer; Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer; Advanced Metastatic Castration-Resistant Prostate Cancer; Advanced Platinum-Resistant Ovarian Cancer Interventions: Drug: TRX518; Drug: Cyclophosphamide; Drug: Avelumab Sponsors: Leap Therapeutics, Inc.; Pfizer; Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Germany Health | Hormones | Pfizer | Prostate Cancer | Research | Study